

Role of smooth muscle-derived vascular progenitor cells in atherosclerosis

Allison M. Dubner^{1, 2}, Sizhao Lu¹, Marie F. Mutryn¹, Austin J. Jolly¹, Keith A. Strand¹, Natalie Navarro¹, Karen S. Moulton³, Raphael A. Nemenoff¹, Mary C.M. Weiser-Evans¹

¹University of Colorado School of Medicine, Division of Renal Diseases & Hypertension, ²University of Colorado Integrated Physiology PhD Program, ³University of Colorado School of Medicine, Division of Cardiology

Athemas alemas is in a maximum access of manufaction and manufaction.

- Atherosclerosis is a major cause of morbidity and mortality worldwide, but current therapies fail to meet clinical needs.
- Expansion of adventitial microvessels, the vasa vasorum (VV), is believed to drive atherosclerosis progression by facilitating inflammatory cell infiltration.




Image adapted from https://www.earthslab.com/physiology/vasa-vasorum/

YFP (Gli1+) Sca1 DAPI

Lu, Sizhao, et al. "Smooth muscle–derived progenitor cell myofibroblast differentiation through KLF4 downregulation promotes arterial remodeling and fibrosis." *JCI*

In vitro studies demonstrated that AdvSca1-

endothelial cells (ECs), and myofibroblasts.


AdvSca1-SM cells contribute to in vivo vessel

formation via differentiation to SMCs or ECs.

SM cells can differentiate into SMCs,

Matrigel plug assays also showed that


- Our group previously identified a unique population of resident stem cells (AdvSca1-SM cells) that derive from mature vascular smooth muscle cells (SMCs) and reside in the vessel adventitia.
- AdvSca1-SM cells are selectively enriched for Gli1 compared to other vascular cells.
- This allowed us to develop the Gli1-Cre/Rosa-YFP mouse model, which selectively and permanently labels AdvSca1-SM cells with YFP, even if they differentiate into other cell types.



Majesky, Mark W., et al. "Differentiated smooth muscle cells generate a subpopulation of resident vascular progenitor cells in the adventitia

Hypothesis

In atherosclerosis, AdvSca1-SM cells will reprogram into smooth muscle or endothelial cells to contribute to vasa vasorum expansion and plaque progression.



Methods

8 weeks

Mice randomized to treatment group at 6-8 weeks of age:

-- Control: IP tamoxifen + standard chow

-- Athero: IP tamoxifen + RO PCSK9 (0, 2, 16, 24 weeks) + Western diet

16 weeks

Mice harvested at 8, 16, 24, or 30 weeks for histology, flow cytometry, or scRNA-Seq

PCSK9 PCSK9

PCSK9

PCSK9


PCSK9


Atherogenic or Standard Diet


Created with Biorender.com

24 weeks


30 weeks







Results





IP Tamoxifen

12 days


t = 0

2 weeks





- AdvSca1-SM cells are mainly found in the stem, SMC, and fibroblast clusters—minimal contribution to ECs or macs.
- Major shift in phenotype of AdvSca1-SM stem cell reservoir in athero.
- Major shifts in SMC and macrophage phenotypes in athero.



Conclusions & Future Directions

- AdvSca1-SM cells are associated with adventitial microvessels after 16 weeks of atherogenic treatment.
- In both early and late stages of atherosclerosis, there is a large reservoir of AdvSca1-SM cells in a stem-like state.
 However, this population shows significant phenotypic shifts in atherogenic compared to control conditions.
- When AdvSca1-SM cells differentiate into other cell types in atherosclerosis, they primarily become mature SMCs, modulated SMCs, and myofibroblasts. AdvSca1-SM cells very rarely become endothelial cells or macrophages.
- Ongoing work with advanced lesions (24-30 weeks of treatment) will more fully define the functional role and spatial localization of AdvSca1-SM cells in atherosclerotic plaque progression.

Acknowledgements

- Integrated Physiology PhD Program
- CCTSI TL1 TOTTS Program
- Weiser-Evans and Nemenoff labs
- Thesis Committee
- Andrew Glugla
- Funding: TL1TR002533 (Dubner), NHLBI F31 HL160149-01 (Dubner), R01 HL121877 (Weiser-Evans/Majesky)